

# TRANSITIONING FROM STERRAD CYCLESURE™ → to STERRAD VELOCITY™

With the advantages of the fluorescence technology utilized by ASP™, releasing an instrument load with safety has been made fast and efficient!

Replacing the 24hrs STERRAD CYCLESURE™ Biological Indicator with the rapid STERRAD VELOCITY™ Biological Indicator/ PCD allows you to:



**01**  
**Reduce infection risks by releasing your instrument load in just 15'**

15 minutes\* compared to 24 hours allows you to release your load only after you have received the BI outcome and not before, meeting the requirements of demanding OR schedules.



**02**  
**Enhance compliance to reprocessing guidelines**

More and more global standards\*\* recommend using biological indicators in every cycle to ensure necessary conditions are met to achieve sterilization. Combined with parametric release and IMS, challenging the sterilization process in every cycle creates the ultimate possible control currently available in Low Temperature Sterilization.



**03**  
**Use a Process Challenge Device in every cycle**

**DID YOU KNOW THAT...**

Biological Indicators and Process Challenge Devices represent different levels of challenge in the sterilization process. Biological Indicators are intended to demonstrate whether the conditions were adequate to achieve sterilization.

Process Challenge Devices provide a challenge to the sterilization process that is equal to or greater than the worst-case medical device loads routinely processed. BIs, in general, do not have the requirement to represent worst-case devices per ISO 11138 and FDA guidance.

Now, STERRAD VELOCITY™ is both a Biological Indicator as well as a Process Challenge Device, elevating the sterilization process monitoring standard



**04**  
**Automated correlation† of STERRAD™ cycle & BI records remotely accessible**

Automated record keeping allows CSSDs to demonstrate process compliance and audit readiness, anytime, reducing the risk of liability.



**05**  
**Easy to use**


With integrated scanner and connecting printer, enabling quick & easy BI processing & documentation.



# Are all Biological Indicators/ Process Challenge Devices made equal?

Using an **inaccurate Biological Indicator and Process Challenge Device** can have costly consequences. **False positives can result in higher material and labor costs<sup>††</sup>** from wasted sterilant, instrument rewapping, patient notifications, and antibiotics, as well as delayed instrument turnaround and unnecessary recalls.

To design an accurate Biological Indicator and Process Challenge Device for all STERRAD™ Systems cycles, **the resistance must be carefully calibrated** to not over or under challenge each cycle. To achieve this delicate balance, ASP leveraged its knowledge of the proprietary cycle parameters and data from more than **15,000 in-use STERRAD™ System cycles**.



The **STERRAD VELOCITY™ BI System / PCD** is fully validated with **STERRAD™ Systems** and ensures only devices with assured sterility reach the patient, helping to minimise the risk of HAI.

The only **all-in-one PCD** for use in **STERRAD™ Systems** that meets AAMI guidelines and other global standards\* and provides sterility assurance by providing a resistance greater than the worst case hospital loads.



## WHAT YOU need to do:



Contact your local ASP representative today and **ask for a loyalty offer** for our STERRAD CYCLESURE™ customers!



Get access to a level of confidence inspired by the only BI/PCD designed by ASP specifically for all **STERRAD™ System Cycles**



[asp.com](http://asp.com)

**ASP** Advanced Sterilization Products

ASP International GmbH, Zug Branch  
Bahnhofstrasse 2, Zug 6300, Switzerland  
©ASP 2021. All Rights Reserved.



ADVANCED STERILIZATION PRODUCTS, INC.  
33 Technology Drive, Irvine CA 92618, USA

\* 15 or 30min to result dependent on the software version on the STERRAD VELOCITY™ Reader.  
15 minutes to result SW version 1139260410 or greater, 30 minutes to result for SW version 1139260317 or below.  
The implementation of the software upgrade in EMEA, will occur in phases. Please contact your local representative to know more.

† Global BI/PCD standards: ANS/AAMI ST58:2013/(R)2018, AAMI TIR31:2008, AORN (2019), Guidelines for Perioperative Practice, AAMI ST79:2017, US FDA (2007).

† Automated integration of information requires connection to ASP ACCESS™ Technology.

†† TR-20416 False Positive Readout using Fluorescent Biological Indicators in the STERRAD 100NX™ Express Cycle;

†† Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039-2046.